SK acquires approval of first ‘Vimpat’ generic, next-generation epilepsy therapy
SK Chemicals acquired a permit to commercialize the first generic of ‘Vimpat Tab(lacosamide)’ that is known as a next-generation epilepsy therapy.
According to the industry on the 1st, SK Chemicals acquired approval of ‘Vimsk Tab,’ a Vimpat’s generic drug, on the 31st for the first time in Korea...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
